Drugs / penicillamine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CUPRIMINE | — | 1970-12-04 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03957720 | Mar 2019 → Dec 2024 | Wilson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06103617 | Nov 2023 → Oct 2024 | head and neck cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT00003751 | Mar 1999 → Jun 2004 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03539952 | Sep 2018 → Aug 2020 | Wilson disease | Orphalan | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01374282 | — | scleroderma | Merck Sharp & Dohme LLC | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05047523 Comparator | Sep 2021 → Jun 2023 | Wilson disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03403205 Comparator | Feb 2018 → Jun 2023 | Wilson disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Penicillamine | “Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines,...” NCT05047523 ↗6“Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered...” NCT03403205 ↗ |
| Known as | Cuprimine | “Cuprimine (penicillamine)” NCT01374282 ↗ |
| Route | Oral | “Patients receive oral penicillamine on the following schedule:” NCT00003751 ↗ |